Description:
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in
combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that
can be given without causing severe side effects. This study will also test the safety of
this combination and see what effects (good or bad) it has on participants and their cancer.
Title
- Brief Title: Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
- Official Title: Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Clinical Trial IDs
- ORG STUDY ID:
EXP-16-01
- NCT ID:
NCT03023319
Conditions
- Carcinoma, Non-Small-Cell Lung
- Mesothelioma
- Bladder Cancer
- Ovarian Cancer
- Peritoneal Cancer
- Thymoma
- Thymus Cancer
- Uterine Cervical Cancer
Interventions
Drug | Synonyms | Arms |
---|
Bosutinib | | Bosutinib and Pemetrexed |
Pemetrexed | | Bosutinib and Pemetrexed |
Purpose
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in
combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that
can be given without causing severe side effects. This study will also test the safety of
this combination and see what effects (good or bad) it has on participants and their cancer.
Trial Arms
Name | Type | Description | Interventions |
---|
Bosutinib and Pemetrexed | Experimental | Bosutinib and pemetrexed | |
Eligibility Criteria
Inclusion Criteria:
- Pathologically or cytologically proven advanced, metastatic non-squamous non-small
cell lung cancer, pleural malignant mesothelioma, bladder or urethral cancer, ovarian
cancer, primary peritoneal cancer, thymoma and thymic cancer and uterine cervical
cancer.
- Measurable disease
- Life expectancy of greater than 3 months.
- Ability to take folic acid, vitamin B12, and dexamethasone according to protocol.
Exclusion Criteria:
- Untreated or symptomatic brain metastases.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Dose-limiting toxicity of the combination of bosutinib and pemetrexed |
Time Frame: | 21 days |
Safety Issue: | |
Description: | CTCAE Grade 3 or 4 non-hematologic toxicities other than alopecia, nausea and vomiting. |
Secondary Outcome Measures
Measure: | Adverse events of the combination of bosutinib and pemetrexed |
Time Frame: | 16 weeks |
Safety Issue: | |
Description: | |
Measure: | Anti-tumor response rate |
Time Frame: | 6 and 12 weeks |
Safety Issue: | |
Description: | |
Measure: | Progression-free survival |
Time Frame: | 6 and 12 weeks |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Nagla Abdel Karim |
Last Updated
August 3, 2021